Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 170.00 GBp
Change Today 0.00 / 0.00%
Volume 308.9K
VEC On Other Exchanges
As of 11:35 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

171.00 GBp
Previous Close
170.00 GBp
Day High
172.00 GBp
Day Low
168.20 GBp
52 Week High
09/9/15 - 187.50 GBp
52 Week Low
11/28/14 - 127.00 GBp
Market Cap
Average Volume 10 Days
0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company’s marketed products include Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; and Extraneal for the treatment of peritoneal dialysis, as well as Asmasal and Asmabec for the treatment of asthma. Its generic products include VR315, VR506, and VR632 for the treatment of asthma; and Phase III clinical stage products include VR475 for the treatment of severe adult asthma, and VR876 for the treatment of pulmonary hypertension, as well as NVA237 and QVA149 for the treatment of COPD for which filed NDA to the Food and Drug Administration. Its Phase II clinical stage products comprise VR096 for anti-inflammatory asthma and COPD; VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; and VR736 for the treatment severe influenza. The company’s Phase I clinical stage products include VR475 for the treatment of severe adult asthma; and VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases. The company also provides drug delivery technology platforms, such as PowderHale, a formulation technology that is designed to enhance the performance of dry powder inhaler products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides dry powder inhalers; nebulizer delivery systems; and AKITA Jet, APIXNEB, and FOX devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

297 Employees
Last Reported Date: 06/15/15
Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 127.0K GBP
Chief Operations Officer, Director and Presid...
Total Annual Compensation: 506.0K GBP
Compensation as of Fiscal Year 2015.

vectura group plc (VEC) Key Developments

Vectura Group plc Confirms the Information Released by Novartis Announcing Positive First Results from the Phase III Flame Head-To-Head Trial

Vectura Group plc confirmed the information released by Novartis announcing positive first results from the Phase III FLAME head-to-head trial examining the rate of chronic obstructive pulmonary disease (COPD) exacerbations. Once-daily Ultibro® Breezhaler (indacaterol/glycopyrronium) 110/50 mcg met its primary endpoint (non-inferiority) and furthermore demonstrated superiority to twice-daily Seretide salmeterol/fluticasone 50/500 mcg in reducing the rate of all COPD exacerbations (mild/moderate/severe) over one year of treatment. This finding is consistent with the earlier LANTERN trial and is now expanded to patients with at least one exacerbation in the previous year. The safety profiles of the two treatments were consistent with their known profiles, according to the initial FLAME results. The full FLAME study results, including data from further secondary endpoints, will be reported at an appropriate scientific forum in due course.

Vectura Group plc Reports Unaudited Earnings Results for the Six Months Ended September 30, 2015

Vectura Group plc reported unaudited earnings results for the six months ended September 30, 2015. For the period, the company reported revenues up 35% to £26.1 million against £19.4 million a year ago. EBITDA up 57% to £4.7 million against £3.0 million a year ago. Loss before tax was £5.0 million against loss of £8.7 million a year ago. Basic EPS loss was 0.7 pence against 1.4 pence a year ago.

Vectura Group plc, H1 2016 Earnings Call, Nov 17, 2015

Vectura Group plc, H1 2016 Earnings Call, Nov 17, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 170.00 GBp 0.00

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VEC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VEC Industry Range
Price/Earnings 100.0x
Price/Sales 10.6x
Price/Book 3.1x
Price/Cash Flow 26.5x
TEV/Sales 10.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VECTURA GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at